Trial · NCT00699335
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient's Assessment of Pain Severity Score | Before and after therapy with Matrifen® (4 weeks) | Assessment on a Visual Analogue Scale from 0=No pain to 10=Most severe pain |
| Primary | Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
| Primary | EQ-5D (Optional): Domain Mobility | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems in walking around 2. I have some problems in walking around 3. I am confined to bed |
| Primary | EQ-5D (Optional): Domain Self Care | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with self-care 2. I have some problems washing or dressing myself 3. I am unable to wash or dress myself |
| Primary | EQ-5D (Optional): Domain Usual Activities | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with performing my usual activities 2. I have some problems with performing my usual activities 3. I am unable to perform my usual activities |
| Primary | EQ-5D (Optional): Pain / Discomfort | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no pain or discomfort 2. I have moderate pain or discomfort 3. I have extreme pain or discomfort |
| Primary | EQ-5D (Optional): Domain Anxiety / Depression | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I am not anxious or depressed 2. I am moderately anxious or depressed 3. I am extremely anxious or depressed |
| Primary | EQ-5D (Optional): European Index Score | Before and after therapy with Matrifen® (4 weeks) | Index derived from the five EQ-5D-items (= mobility, self care, usual activities, pain/discomfort, anxiety/depression) resulting in a value from -1= very ill to 1=full health |
| Primary | EQ-5D (Optional): Visual Analogue Scale | Before and after therapy with Matrifen® (4 weeks) | Visual Analogue Scale (VAS) from 0 =worst imaginable health status, 100 =best imaginable health status |
| Secondary | Physician's Assessment of the Skin Tolerability of the Fentanyl-patches | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
| Secondary | Patient's Assessment of the Acceptance of the Fentanyl-patches | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
| Secondary | Physician's Assessment of the Adhesion Properties of the Fentanyl-patches | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
| Secondary | Physician's Final Assessment of the Tolerability of Matrifen® | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00699335/registered